A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)
NCT ID: NCT06701513
Last Updated: 2025-04-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
350 participants
OBSERVATIONAL
2025-01-29
2028-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
NCT05701995
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
NCT03757013
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
NCT05744466
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT06979453
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
NCT04772079
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants that have initiated deucravacitinib treatment
Deucravacitinib
As prescribed by treating clinician
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Deucravacitinib
As prescribed by treating clinician
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Physician-reported diagnosis of moderate to severe plaque psoriasis
* Be newly initiating deucravacitinib
* Do not object to participate
Exclusion Criteria
* Previous treatment experience with deucravacitinib, including patients who received deucravacitinib as part of a blinded, randomized trial
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution - 060
Amiens, , France
Cabinet Médical Elisabeth Lion
Angers, , France
Local Institution - 045
Argenteuil, , France
CH ARRAS
Arras, , France
Local Institution - 041
Bordeaux, , France
Local Institution - 048
Bordeaux, , France
Centre Hospitalier William Morey - Hématologie
Chalon-sur-Saône, , France
CHU Dijon
Dijon, , France
Local Institution - 077
Dijon, , France
Local Institution - 011
La Tronche, , France
Local Institution - 074
Le Puy-en-Velay, , France
Local Institution - 039
Lens, , France
Local Institution - 004
Marcq-en-Barœul, , France
Local Institution - 036
Montpellier, , France
Local Institution - 012
Nice, , France
Local Institution - 008
Niort, , France
Local Institution - 070
Niort, , France
Local Institution - 062
Nîmes, , France
Local Institution - 073
Paris, , France
Local Institution - 078
Périgueux, , France
Local Institution - 046
Roubaix, , France
Local Institution - 047
Roubaix, , France
Local Institution - 051
Saint-Mandé, , France
Local Institution - 072
Saint-Maur-des-Fossés, , France
Hia Sainte Anne
Toulon, , France
Local Institution - 054
Toulon, , France
Local Institution - 005
Toulouse, , France
Local Institution - 021
Toulouse, , France
Local Institution - 037
Toulouse, , France
Local Institution - 061
Vandœuvre-lès-Nancy, , France
Local Institution - 064
Vandœuvre-lès-Nancy, , France
Local Institution - 003
Villeurbanne, , France
Local Institution - 006
Villeurbanne, , France
Cabinet Medical
La Chaux-de-Fonds, , Switzerland
Cabinet Medical
La Chaux-de-Fonds, , Switzerland
Local Institution - 007
La Chaux-de-Fonds, , Switzerland
Local Institution - 025
La Chaux-de-Fonds, , Switzerland
Local Institution - 029
La Chaux-de-Fonds, , Switzerland
Local Institution - 038
La Chaux-de-Fonds, , Switzerland
Local Institution - 044
La Chaux-de-Fonds, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
BMS Study Connect Contact Center www.BMSStudyConnect.com
Role: CONTACT
First line of the email MUST contain NCT # and Site #.
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Site 060
Role: primary
ANGELIQUE MARCHAND, Site 009
Role: primary
Site 045
Role: primary
CELINE DESVIGNES, Site 010
Role: primary
Site 041
Role: primary
Site 048
Role: primary
MARIE DHERS, Site 001
Role: primary
Camille LELEU, Site 002
Role: primary
Site 077
Role: primary
Site 011
Role: primary
Site 074
Role: primary
Site 039
Role: primary
Site 004
Role: primary
Site 036
Role: primary
Site 012
Role: primary
Site 008
Role: primary
Site 070
Role: primary
Site 062
Role: primary
Site 073
Role: primary
Site 078
Role: primary
Site 046
Role: primary
Site 047
Role: primary
Site 051
Role: primary
Site 072
Role: primary
Thierry Boye, Site 055
Role: primary
Site 054
Role: primary
Site 005
Role: primary
Site 021
Role: primary
Site 037
Role: primary
Site 061
Role: primary
Site 064
Role: primary
Site 003
Role: primary
Site 006
Role: primary
NICOLE JOUAN, Site 015
Role: primary
BENOIT BEN SAID, Site 016
Role: primary
Site 007
Role: primary
Site 025
Role: primary
Site 029
Role: primary
Site 038
Role: primary
Site 044
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM011-1127
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.